<DOC>
	<DOCNO>NCT02513563</DOCNO>
	<brief_summary>The purpose study find effect ( good bad ) AZD1775 use combination carboplatin paclitaxel participant cancer .</brief_summary>
	<brief_title>AZD1775 Plus Carboplatin-Paclitaxel Squamous Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Histologic cytological diagnosis Squamous Cell Lung Cancer ( SQCLC ) advanced/metastatic stage , know curative treatment option . Prior platinumcontaining adjuvant , neoadjuvant , definitive chemoradiation therapy give locally advanced disease consider first line therapy recurrent ( local metastatic ) disease develop within 6 month complete therapy . Potential participant recurrent disease &gt; 6 month eligible . Female male age &gt; /= 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0/1 Prior chemotherapy adjuvant setting allow Prior radiotherapy allow Prior Immunotherapy PD1i , PDL1i , antiCTLA 4 vaccine allow Must normal organ marrow function Have archival tissue available undergo fresh biopsy clinically feasible discussion sponsor Women childbearing potential men must agree use adequate contraception prior study entry duration study participation woman breast feed exclude study . Both woman men fully inform lack reproductive toxicity testing , woman must negative pregnancy test prior enrolment . Progressive , symptomatic untreated brain metastasis Pregnancy breast feed A serious uncontrolled medical disorder active infection investigator 's opinion would impair participant 's ability receive study treatment Prior use platinum paclitaxel stage IV Nonsmall Cell Lung Cancer ( NSCLC ) concurrent use anticancer approve investigational agent Known Hepatitis B C HIV infection Second primary malignancy , situ malignancy adequately treat basal cell carcinoma skin malignancy treat least 2 year previously evidence recurrence Have prescription nonprescription drug product ( i.e. , grapefruit juice ) know sensitive CYP3A4 substrates CYP3A4 substrate narrow therapeutic index , moderate strong inhibitor inducer CYP3A4 , discontinue 2 week Day 1 dose withheld throughout study 2 week last dose study drug Coadministration aprepitant fosaprepitant study prohibit AZD1775 inhibitor breast cancer resistance protein ( BCRP ) . The use statins include Atorvastatin substrates BCRP therefore prohibit patient move nonBCRP alternative . Herbal preparation allow throughout study . These herbal medication include , limited : St. John 's wort , kava , ephedra ( huang ) , gingko biloba , dehydroepiandrosterone ( DHEA ) , yohimbe , saw palmetto , ginseng .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Squamous cell lung cancer</keyword>
</DOC>